Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Amphotericin B Analog
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Deerfield Management
Deal Size : $81.0 million
Deal Type : Series B Financing
Elion Therapeutics Closes $81 Million Series B Funding Led by Deerfield & AMR Action Fund
Details : Elion's clinical-stage candidate, SF001 (Amphotericin B Analog), polyene antifungal, completed a first-in-human single-ascending dose study and is now being evaluated for invasive aspergillosis.
Product Name : SF001
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
June 17, 2024
Lead Product(s) : Amphotericin B Analog
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Deerfield Management
Deal Size : $81.0 million
Deal Type : Series B Financing
Reset All
